QIAGEN N.V. and Incyte announced a new global collaboration on June 17, 2025, to develop a novel diagnostic panel. This panel will support Incyte’s investigational therapies for patients with myeloproliferative neoplasms (MPNs), a group of rare blood cancers, including Incyte’s monoclonal antibody INCA033989 targeting mutant calreticulin (mutCALR).
Under the Master Collaboration Agreement, QIAGEN will develop a multimodal panel using next-generation sequencing (NGS) technology for detecting clinically relevant gene alterations in hematological malignancies. The panel will be validated on the Illumina NextSeq 550Dx platform, leveraging QIAGEN’s partnership with Illumina.
QIAGEN will also support regulatory submission processes and market access activities across the United States, European Union, and Asia-Pacific regions. This partnership strengthens QIAGEN’s role in offering companion diagnostics for the growing number of biomarkers in onco-hematology, aiming to improve patient outcomes through personalized treatment decisions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.